Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687713 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence
A Phase 2 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00687713 is a Phase 2 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 200 participants.
The verdict
NCT00687713, a Phase 2 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.
Interventions
- OTHER Placebo
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2008-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00687713
The ClinicalTrials.gov registry entry for NCT00687713 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00687713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00687713 about?
NCT00687713 is a clinical study titled "Phase 2, Double-Blind, Placebo-Controlled Trial of Bupropion for Methamphetamine Dependence". This study is to assess the efficacy of bupropion in reducing methamphetamine use in subjects with methamphetamine dependence who report using methamphetamine 29 or less days during the 30 days prior to the start of signing consent.
What is the current status of trial NCT00687713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2008-05. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00687713?
The interventions under investigation include: Placebo (OTHER), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00687713?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.